普众发现医药科技（上海）有限公司（Multitude Therapeutics）是一个平台型创新制药公司，于2019年6月成立于上海和硅谷。拥有领先的新靶标技术平台，包括MabArray™，“肿瘤靶标全图”和“活细胞表面抗体组”。目前普众已经拥有超过10个基于全新靶标的制药项目，其中多个项目已经进入人体试验。基于这些新靶标的普适性，我们同时在开发双特异（Bi-specific）和ADC。
Employees: 11-50
Investors 1
| Date | Name | Website |
| 19.03.2022 | Northern L... | nlvc.com |
Mentions in press and media 6
| Date | Title | Description |
| 19.10.2025 | Multitude Therapeutics Announces Encouraging Interim Phase I/II Results from Ongoing First-in-Human Study Evaluating its MUC18-directed Antibody-Drug-Conjugate, AMT-253, in Melanoma and Other Advanced... | AMT-253 is a potential first-in-class MUC18-directed ADC with a proprietary linker-payload design AMT-253 demonstrated a manageable safety profile, consistent with other TOP1-inhibitor based ADCs Promising antitumor activity was observed in... |
| 23.06.2025 | OnCusp Therapeutics Appoints Dimitry Nuyten, M.D., Ph.D., as Chief Medical Officer | PRINCETON, N.J., June 23, 2025 /PRNewswire/ -- OnCusp Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated to transforming cutting-edge preclinical innovation into clinically validated treatments for cancer patients, tod... |
| 02.06.2025 | OnCusp Therapeutics Announces Encouraging Initial Phase 1a Results from Ongoing First-in-Human Study Evaluating its CDH6-Directed Antibody-Drug Conjugate, CUSP06, in Platinum-Refractory/Resistant Ovar... | CUSP06 is a CDH6-directed ADC with a differentiated profile and potentially best-in-class activity CUSP06 demonstrated a manageable safety profile, consistent with other TOP1-inhibitor ADCs Promising signs of efficacy were observed in patie... |
| 13.02.2025 | OnCusp Therapeutics: A New Hope for Ovarian Cancer Patients | In the realm of cancer treatment, hope often feels like a flickering candle in a storm. Yet, OnCusp Therapeutics is igniting that flame with its recent FDA Fast Track Designation for CUSP06, a promising therapy for platinum-resistant ovaria... |
| 12.02.2025 | OnCusp Therapeutics Receives FDA Fast Track Designation for CUSP06 for the Treatment of Platinum-Resistant Ovarian Cancer | PRINCETON, N.J., Feb. 12, 2025 /PRNewswire/ -- OnCusp Therapeutics, Inc., a clinical stage biopharmaceutical company dedicated to transforming cutting-edge preclinical innovation into clinically validated treatments for cancer patients, tod... |
| 31.01.2024 | WuXi XDC Enters into Partnership with Multitude Therapeutics and HySlink Therapeutics, Novel Linker-Payload Technology Enabling Clients to Accelerate ADC Discovery and Development | SHANGHAI, Jan. 31, 2024 /PRNewswire/ -- WuXi XDC (2268.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO) focused on ADC and the other types of bioconjugate market; and Multitude Therapeutics, a clin... |